What is the official website of Novartis Nederland ?

The official website of Novartis Nederland is https://www.novartis.nl/.

What is Novartis Nederland's cybersecurity risk score?

Novartis Nederland has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Nederland experienced?

According to Rankiteo, Novartis Nederland currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Nederland been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Nederland has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Nederland have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Nederland is not certified under SOC 2 Type 1.

Does Novartis Nederland have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Nederland does not hold a SOC 2 Type 2 certification.

Does Novartis Nederland comply with GDPR ?

According to Rankiteo, Novartis Nederland is not listed as GDPR compliant.

Does Novartis Nederland have PCI DSS certification ?

According to Rankiteo, Novartis Nederland does not currently maintain PCI DSS compliance.

Does Novartis Nederland comply with HIPAA ?

According to Rankiteo, Novartis Nederland is not compliant with HIPAA regulations.

Does Novartis Nederland have ISO 27001 certification ?

According to Rankiteo,Novartis Nederland is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Nederland operate in ?

Novartis Nederland operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Nederland have ?

Novartis Nederland employs approximately 135 people worldwide.

Does Novartis Nederland own any subsidiaries ?

Novartis Nederland presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Nederland have ?

Novartis Nederland's official LinkedIn profile has approximately 9,449 followers.

What is the NAICS classification code for Novartis Nederland ?

Novartis Nederland is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Nederland have a Crunchbase profile ?

No, Novartis Nederland does not have a profile on Crunchbase.

Does Novartis Nederland have a LinkedIn profile ?

Yes, Novartis Nederland maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-pharma-nederland.

How many cybersecurity incidents has Novartis Nederland experienced ?

As of June 20, 2026, Rankiteo reports that Novartis Nederland has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Nederland have ?

Novartis Nederland has an estimated 5,695 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Nederland faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Nederland

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Novartis Nederland Vendor Cyber Rating & Cyber Score

novartis.nl

Add Your Compliance Badge

Novartis is een farmaceutisch bedrijf uit Zwitserland dat gedreven een betekenisvolle bijdrage wil leveren aan de gezondheidszorg. Door steeds de laatste inzichten uit de wetenschap om te zetten naar innovatieve behandelingen, proberen we betere resultaten voor patiënten over de hele wereld te realiseren. In onze zoektocht naar nieuwe medicijnen behoren we consequent tot 's werelds topbedrijven die aanzienlijk investeren in onderzoek en ontwikkeling. Wereldwijd bereiken de producten van Novartis zo'n 800 miljoen mensen. Onze missie is om de kwaliteit van leven van patiënten te verbeteren en hun levensduur te verlengen. Er werken wereldwijd ongeveer 107.000 mensen met 140 nationaliteiten bij Novartis. Bij Novartis Nederland werken rond

Novartis Nederland A.I CyberSecurity Scoring

Scoring History

Novartis Nederland

Novartis Nederland CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Nederland

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Nederland Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Nederland

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Nederland in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Nederland in 2026.

Incident Types Novartis Nederland vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Nederland in 2026.

Incident History - Novartis Nederland (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Nederland Subsidiaries

Novartis Nederland

Pharmaceutical Manufacturing

Website: https://www.novartis.nl/

Company Size: 135

Novartis Nederland - ReumatologieGeneesmiddelenproductie

NovartisPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Loading…

Novartis Nederland Similar Companies

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Loading…

NEWS

Novartis Nederland CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

May 20, 2025 07:00 AM

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Role models for students, parents, educators, and the cybersecurity community Sponsored by Secureworks.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56082

SUMMARY

Capgo (Cap-go/capgo) before 12.128.2 contains an improper access control vulnerability in the SECURITY DEFINER PostgREST RPC function public.record_build_time, which is granted to the anon role and callable with only the public Supabase publishable (sb_publishable_*) anon key. An unauthenticated attacker can insert rows into public.build_logs for arbitrary organizations and, because the function uses ON CONFLICT (build_id, org_id) DO UPDATE, can overwrite existing usage/billing records by reusing the same build_id for a target org. This enables cross-tenant tampering of billing build logs and financial-impact denial of service by inflating billable build time.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:N

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56081

SUMMARY

Cap-go before 12.128.2 contains an authentication logic flaw that lets an attacker register and control an account bound to a victim's email address before that email is verified. By enabling two-factor authentication on the pre-registered account, the attacker gains control over the account claimed under the victim's identity, allowing them to read and modify its state and enforce organization-level policies, while the legitimate user is denied access to the account tied to their own email.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 9.1)

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

3.9

REFERENCES

CVE-2026-56080

SUMMARY

Capgo before 12.128.2 contains a flaw in the Enforce Password Policy feature: after a Super Admin enables the policy and successfully changes their password to a compliant one, the backend does not update the password-compliance state. As a result, the backend continues to treat the account as non-compliant and repeatedly forces password-reset prompts, permanently locking the Super Admin out of organization access (organization lockout / denial of service) despite valid authentication.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 4.9)

cvss3

Base Score: 4.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

1.2

REFERENCES

CVE-2026-56079

SUMMARY

Capgo before 12.128.2 contains a cross-tenant authorization bypass vulnerability in PostgREST endpoints that allows org-scoped read API keys to access other tenants' webhook secrets and delivery logs. Attackers can query the webhooks and webhook_deliveries endpoints to exfiltrate HMAC signing secrets and delivery payloads, enabling forged webhook events against victim organizations.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-56073

SUMMARY

Cap-go before 12.128.2 contains an authentication bypass vulnerability in OTP verification that allows attackers to bypass email verification by modifying server responses. Attackers can intercept OTP verification requests and manipulate HTTP responses to falsely mark verification successful, enabling unauthorized 2FA enablement and account takeover.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 9.4)

cvss3

Base Score: 9.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:L

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.5

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…